CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.12% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money

Trade Stoke Therapeutics, Inc. - STOK CFD

6.60
7.68%
Market Trading Hours* (UTC) Open now
Closes on Monday at 20:00

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
Trading сonditions
Spread 0.10
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.02354 %
Charges from full value of position ($-0.24)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
-0.02354%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.001318 %
Charges from full value of position ($0.01)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
0.001318%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 50.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 7.16
Open 6.86
1-Year Change -48.77%
Day's Range 6.56 - 6.93
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 28, 2025 7.16 -0.20 -2.72% 7.36 7.43 7.01
Mar 27, 2025 7.39 0.13 1.79% 7.26 7.46 7.26
Mar 26, 2025 7.35 -0.26 -3.42% 7.61 7.61 7.08
Mar 25, 2025 7.70 -0.39 -4.82% 8.09 8.20 7.46
Mar 24, 2025 8.23 0.12 1.48% 8.11 8.38 8.06
Mar 21, 2025 8.10 0.06 0.75% 8.04 8.25 7.62
Mar 20, 2025 8.29 0.33 4.15% 7.96 8.35 7.96
Mar 19, 2025 8.20 -0.66 -7.45% 8.86 8.86 7.98
Mar 18, 2025 8.81 0.22 2.56% 8.59 8.87 7.56
Mar 17, 2025 8.95 0.49 5.79% 8.46 8.98 8.43
Mar 14, 2025 8.55 0.46 5.69% 8.09 8.67 8.09
Mar 13, 2025 8.06 -0.31 -3.70% 8.37 8.45 8.06
Mar 12, 2025 8.47 0.29 3.55% 8.18 8.53 8.02
Mar 11, 2025 8.15 0.44 5.71% 7.71 8.23 7.57
Mar 10, 2025 7.90 0.06 0.77% 7.84 8.00 7.65
Mar 7, 2025 7.95 -0.01 -0.13% 7.96 8.15 7.78
Mar 6, 2025 8.10 0.14 1.76% 7.96 8.13 7.80
Mar 5, 2025 8.12 0.65 8.70% 7.47 8.14 7.47
Mar 4, 2025 7.53 0.28 3.86% 7.25 7.64 7.15
Mar 3, 2025 7.35 -0.38 -4.92% 7.73 7.82 7.26

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
Leverage
2:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Stoke Therapeutics, Inc. Company profile

About Stoke Therapeutics Inc

Stoke Therapeutics, Inc. is a biotechnology company. It focuses to treat the underlying causes of severe genetic diseases by upregulating protein expression. It is developing antisense oligonucleotide (ASO) medicines that target ribonucleic acid (RNA) and modulate precursor-messenger RNA (pre-mRNA) splicing to upregulate protein expression where needed and with appropriate specificity to near normal levels. It focuses to develop the precision medicine platform to target the underlying cause of a spectrum of genetic diseases in which the patient has healthy copy of a gene and mutated copy that fails to produce a protein essential to health. It utilizes its technology platform, Targeted Augmentation of Nuclear Gene Output (TANGO) to design ASOs to upregulate the expression of protein by individual genes in a patient. Its product candidate, STK-001, is offered to treat Dravet syndrome. Its research platform is designed to address protein deficiency.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Stoke Therapeutics Inc revenues was not reported. Net loss increased 64% to $85.8M. Higher net loss reflects Research and development - Balancing val increase of 58% to $48M (expense), Stock-based Compensation in SGA increase from $3.9M to $10.2M (expense), General and administrative - Balancing increase of 28% to $21.7M (expense).

Industry: Biotechnology & Medical Research (NEC)

45 Wiggins Avenue
BEDFORD
MASSACHUSETTS 01730
US

People also watch

Gold

3,123.14 Price
+1.210% 1D Chg, %
Long position overnight fee -0.0162%
Short position overnight fee 0.0080%
Overnight fee time 21:00 (UTC)
Spread 0.30

US100

19,215.60 Price
+0.230% 1D Chg, %
Long position overnight fee -0.0235%
Short position overnight fee 0.0013%
Overnight fee time 21:00 (UTC)
Spread 1.8

BTC/USD

83,491.10 Price
+1.170% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 50.00

ETH/USD

1,844.47 Price
+1.600% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 1.75

Still looking for a broker you can trust?

Join the 710,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading